15
Participants
Start Date
March 31, 2013
Primary Completion Date
July 31, 2014
Study Completion Date
July 31, 2015
Dexmedetomidine
loading dose (0.5 mcg/kg i.v.), followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Study infusion up to 5 days.
University of Minnesota Medical Center, Minneapolis
National Institute of Nursing Research (NINR)
NIH
Hospira, now a wholly owned subsidiary of Pfizer
INDUSTRY
University of Minnesota
OTHER